Prognosis in marginal zone lymphoma: a comprehensive review

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Marginal zone lymphomas (MZLs) are indolent B-cell neoplasms with distinct extranodal, nodal, and splenic subtypes.
• Despite shared features, MZL subtypes exhibit significant clinical heterogeneity influenced by origin site and genetics.
• Disease variability impacts management, therapeutic strategies, and prognosis determination.

Purpose of the Study:

• To review current knowledge on marginal zone lymphoma prognosis.
• To critically evaluate existing prognostic models for MZLs.
• To highlight the clinical utility of risk stratification in MZL management.

Main Methods:

• Literature review synthesizing data on MZL prognosis.
• Critical assessment of established prognostic indices (MALT-IPI, HPLL).
• Evaluation of the comprehensive Marginal Zone Lymphoma International Prognostic Index (MZL-IPI).

Main Results:

• Existing prognostic tools like MALT-IPI and HPLL aid risk assessment in MZL subtypes.
• The MZL-IPI integrates data across all MZL subtypes using validated clinical parameters.
• MZL-IPI offers a comprehensive approach to risk stratification.

Conclusions:

• Accurate prognostic assessment is crucial for tailoring treatment in MZLs.
• The MZL-IPI represents a significant advancement in predicting outcomes for all MZL subtypes.
• Improved risk stratification through models like MZL-IPI can optimize clinical management and patient outcomes.